Cleveland BioLabs Inc.

4.67-0.3600-7.16%Vol 140.45K1Y Perf 197.45%
Apr 20th, 2021 16:00 DELAYED
BID4.71 ASK4.73
Open4.91 Previous Close5.03
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap72.24M 
Earnings Rating
Buy
Price Range Ratio 52W %
33.96 
Earnings Date
21st May 2021

Today's Price Range

4.585.01

52W Range

1.4310.97

5 Year PE Ratio Range

-5.60-1.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-28.59%
1 Month
-24.19%
3 Months
15.02%
6 Months
47.78%
1 Year
197.45%
3 Years
64.44%
5 Years
96.22%
10 Years
-97.17%

TickerPriceChg.Chg.%
CBLI4.67-0.3600-7.16
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
7.50
7.60
-
-
-824.60
Leverage Ratio -1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-983.70
-979.30
-414.70
-
RevenueValueIndustryS&P 500US Markets
106.90K
0.01
-41.97
-36.72
Earnings HistoryEstimateReportedSurprise %
Q02 2020--0.03-
Q01 2020--0.05-
Q03 2019--0.04-
Q02 2019--0.05-
Q01 2019--0.08-
Q03 2018--0.10-
Q01 2018--0.11-
Q04 2017--0.10-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date21st May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume140.45K
Shares Outstanding15.47M
Trades Count796
Dollar Volume1.92M
Avg. Volume367.55K
Avg. Weekly Volume187.46K
Avg. Monthly Volume190.82K
Avg. Quarterly Volume374.54K

Cleveland BioLabs Inc. (NASDAQ: CBLI) stock closed at 4.67 per share at the end of the most recent trading day (a -7.16% change compared to the prior day closing price) with a volume of 140.48K shares and market capitalization of 72.24M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cleveland BioLabs Inc. CEO is Christopher Zosh.

The one-year performance of Cleveland BioLabs Inc. stock is 197.45%, while year-to-date (YTD) performance is 35.36%. CBLI stock has a five-year performance of 96.22%. Its 52-week range is between 1.43 and 10.97, which gives CBLI stock a 52-week price range ratio of 33.96%

Cleveland BioLabs Inc. currently has a PE ratio of -27.90, a price-to-book (PB) ratio of 146.14, a price-to-sale (PS) ratio of 727.86, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -105.76%, a ROC of -% and a ROE of 65.04%. The company’s profit margin is -%, its EBITDA margin is -979.30%, and its revenue ttm is $106.90 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Cleveland BioLabs Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cleveland BioLabs Inc.’s next earnings report date is 21st May 2021.

The consensus rating of Wall Street analysts for Cleveland BioLabs Inc. is (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cleveland BioLabs Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cleveland BioLabs Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cleveland BioLabs Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 33.62, ATR14 : 0.80, CCI20 : -122.52, Chaikin Money Flow : 0.16, MACD : -0.02, Money Flow Index : 61.54, ROC : -4.19, RSI : 42.04, STOCH (14,3) : 8.94, STOCH RSI : 0.00, UO : 52.09, Williams %R : -91.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cleveland BioLabs Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Hold
3.00

Cleveland BioLabs Inc.

Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.

CEO: Christopher Zosh

Telephone: +1 716 849-6810

Address: 73 High Street, Buffalo 14203, NY, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

45%55%

News

Stocktwits